A panelist explains how the distinct mechanisms of erythropoiesis-stimulating agents (ESAs), luspatercept, and imetelstat ...

Bristol Myers Squibb has announced positive topline results from its phase 3 trial of Reblozyl (luspatercept-aamt), the first erythroid maturation agent for first-line treatment of patients with ...

In late 2019, the FDA approved luspatercept -- an erythroid maturation agent administered subcutaneously every 3 weeks -- for the treatment of anemia in adults with thalassemia who require regular ...

Myelodysplastic Syndrome Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035 The report provides a detailed analysis of the current myelodysplastic ...

If approved, it would compete with Bristol-Myers Squibb’s erythroid maturation agent Reblozyl (luspatercept), which was cleared to treat anaemia in adults with low-risk, relapsed MDS in 2020 and ...

It offers REBLOZYL, an erythroid maturation agent for the treatment of anemia in adult patients with beta-thalassemia and transfusion-dependent anemia.

To address this, we systematically analyzed the subcellular location of IDH1 in erythroid cells at different time points on umbilical cord blood-derived CD34 + cells induced to normal human terminal ...

To address this, we systematically analyzed the subcellular location of IDH1 in erythroid cells at different time points on umbilical cord blood-derived CD34 + cells induced to normal human terminal ...

These findings highlight the dual roles of antioxidants in cancer. Their impact depends on cancer type, stage, and genetic ...

Virginia Beach’s latest economic development director has resigned after just months in the role.